| Equity fundraise of £16 million | 20-Oct-2025 | 07:01 | RNS |
| Avacta Presents Phase 1a Data for Faridoxorubicin | 20-Oct-2025 | 07:00 | RNS |
| Avacta to present data at EORTC-NCI-AACR | 13-Oct-2025 | 07:00 | RNS |
| Interim Half Year Results 2025 | 30-Sep-2025 | 07:00 | RNS |
| Notice of Interim Results | 15-Sep-2025 | 07:00 | RNS |
| Avacta completes sale of Coris Bioconcept | 01-Sep-2025 | 07:00 | RNS |
| Amendments to Convertible Bond + equity fundraise | 29-Aug-2025 | 07:00 | RNS |
| Avacta to Present at ESMO Congress | 30-Jul-2025 | 07:00 | RNS |
| Agreement to Sell Coris Bioconcept SRL | 28-Jul-2025 | 07:48 | RNS |
| Payment of Convertible Bond Installment | 21-Jul-2025 | 07:00 | RNS |
| Equity fundraise of £3.25 million | 17-Jul-2025 | 07:00 | RNS |
| Result of AGM | 02-Jul-2025 | 17:00 | RNS |
| Q2 2025 Business Update | 02-Jul-2025 | 07:00 | RNS |
| Management Team Appointments | 01-Jul-2025 | 07:00 | RNS |
| Appointment of Zeus Capital as Joint Broker | 30-Jun-2025 | 15:00 | RNS |
| Currency | UK Pounds |
| Share Price | 63.80p |
| Change Today | 0.30p |
| % Change | 0.47 % |
| 52 Week High | 72.00p |
| 52 Week Low | 27.50p |
| Volume | 3,282,185 |
| Shares Issued | 411.05m |
| Market Cap | £262.25m |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 58,583 @ 63.80p |
| 16:35 | 145 @ 63.80p |
| 16:35 | 362 @ 63.80p |
| 16:35 | 109 @ 63.80p |
| 16:35 | 49 @ 63.80p |
You are here: research